SCHEMBL15328124

SCHEMBL15328124

Cc1[nH]c(/C=C2\C(=O)Nc3cc(NC(=O)NC(=O)c4ccccc4F)ccc32)c(C)c1CCC(=O)O

nearest known ligand 0.80

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FLT3 P36888 12/20 0.80
AURKB Q96GD4 12/20 0.80
KDR P35968 9/20 0.68
FLT4 P35916 4/20 0.68
KIT P10721 1/20 0.68
FGFR1 P11362 6/20 0.62
PDGFRB P09619 5/20 0.62
EGFR P00533 3/20 0.62
AURKA O14965 2/20 0.61
RET P07949 2/20 0.61
FLT1 P17948 2/20 0.61
MAP4K2 Q12851 2/20 0.61
STK3 Q13188 2/20 0.61
GAK O14976 1/20 0.61
RPS6KA5 O75582 1/20 0.61
RPS6KA4 O75676 1/20 0.61
LATS1 O95835 1/20 0.61
CSNK2A2 P19784 1/20 0.61
MAP2K2 P36507 1/20 0.61
ZAP70 P43403 1/20 0.61

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15328126 1.00 FLT3 (0.80) FLT3AURKBKDRFLT4KIT
SCHEMBL15328130 0.92 FLT3 (0.84) FLT3AURKBKDRFLT4KIT
SCHEMBL15328129 0.92 FLT3 (0.84) FLT3AURKBKDRFLT4KIT
SCHEMBL15339414 0.90 FLT3 (0.81) FLT3AURKBKDRFLT4KIT
SCHEMBL15327977 0.89 AURKB (1.00) FLT3AURKBKDRFLT4KIT
SCHEMBL15327979 0.89 AURKB (1.00) FLT3AURKBKDRFLT4KIT
SCHEMBL15328142 0.88 FLT3 (0.83) FLT3AURKBKDRFLT4KIT
SCHEMBL15328140 0.88 FLT3 (0.83) FLT3AURKBKDRFLT4KIT
SCHEMBL15327920 0.87 FLT3 (0.79) FLT3AURKBKDRFLT4KIT
SCHEMBL15327921 0.87 FLT3 (0.79) FLT3AURKBKDRFLT4KIT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2838531-B1 INDOLIN-2-ONE DERIVATIVES AS PROTEIN KINASE INHIBITORS ANNJI PHARM CO LTD (CN) 2016-09-21 EP claimed
US-8946282-B2 Indolin-2-one derivatives as protein kinase inhibitors Annji Pharmaceutical Co., Ltd. (TW) 2015-02-03 US claimed
US-20130281451-A1 INDOLIN-2-ONE DERIVATIVES AS PROTEIN KINASE INHIBITORS Annji Pharmaceutical Co., Ltd. (TW) 2013-10-24 US claimed
EP-2838531-B1 INDOLIN-2-ONE DERIVATIVES AS PROTEIN KINASE INHIBITORS ANNJI PHARM CO LTD (CN) 2016-09-21 EP disclosed
US-8946282-B2 Indolin-2-one derivatives as protein kinase inhibitors Annji Pharmaceutical Co., Ltd. (TW) 2015-02-03 US disclosed
US-8946282-B2 Indolin-2-one derivatives as protein kinase inhibitors Annji Pharmaceutical Co., Ltd. (TW) 2015-02-03 US disclosed
US-8946282-B2 Indolin-2-one derivatives as protein kinase inhibitors Annji Pharmaceutical Co., Ltd. (TW) 2015-02-03 US disclosed
US-20130281451-A1 INDOLIN-2-ONE DERIVATIVES AS PROTEIN KINASE INHIBITORS Annji Pharmaceutical Co., Ltd. (TW) 2013-10-24 US disclosed
US-20130281451-A1 INDOLIN-2-ONE DERIVATIVES AS PROTEIN KINASE INHIBITORS Annji Pharmaceutical Co., Ltd. (TW) 2013-10-24 US disclosed
US-20130281451-A1 INDOLIN-2-ONE DERIVATIVES AS PROTEIN KINASE INHIBITORS Annji Pharmaceutical Co., Ltd. (TW) 2013-10-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130281451-A1 INDOLIN-2-ONE DERIVATIVES AS PROTEIN KINASE INHIBITORS ING2, CDK2, MAP3K20 FLT3 1086/4885AURKB 100/4885KDR 1519/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.